米国企業
ADMA BIOLOGICS, INC.

ADMA BIOLOGICS, INC.ADMA

時価総額

$23.9億

PER

	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
NET LOSS	-7,301,313	-15,527,246	-16,813,163	-17,969,930	-19,515,151	-43,758,975	-65,743,445	-48,279,317	-75,748,548	-71,647,618	-65,903,950	-28
Depreciation and amortization	182,089	210,633	247,852	469,821	469,576	3	3	3	4	5	7	8
Loss on disposal of fixed assets	-18,399	-	-	-	-	-10,144	-122,190	-207,071	81,697	-220,761	-426,536	-0
Interest paid in kind	-	-	-	-	-	-	-	-	-	-	3	4
Stock-based compensation	626,787	888,295	1	2	1	2	2	3	3	3	5	6
Amortization of debt discount	2,869	91,704	133,197	353,635	676,943	781,567	1	1	2	2	2	3
Loss on extinguishment of debt	-	-	-	-719,097	-	-1,210,216	-	-9,962,495	991,797	-	-6,669,941	-26
Amount of noncash revenue related to amortization of license revenue.	-	-	-	-	-	-	-	-	-142,834	-142,834	-142,834	-0
Accounts receivable	-39,112	39,112	383,961	540,507	93,559	3	-2,487,713	2	-9,767,371	15	-13,071,809	12
Inventories	118,248	403,465	39,704	2	2	-589,318	6	35	-28,470,864	43	39	10
Prepaid expenses and other current assets	-	-	-	-	-	-	-	-	-	1	755,900	0
Amount of increase (decrease) in deposits and operating assets classified as other.	-	-	-	-	-	-	-	-	-	2	-122,468	-1
Accounts payable	-244,743	2	-937,779	308,658	476,826	3	-20,480	3	2	1	799,981	4
Accrued expenses	150,622	76,471	1	-199,615	416,972	614,483	406,984	806,353	3	8	8	8
Other current and non-current liabilities	-	-	-	-	-	-	174,434	-190,514	-	218,580	-502,238	-1
Net cash provided by (used in) operating activities	-6,903,795	-10,887,154	-14,704,910	-15,418,404	-18,268,973	-37,271,774	-62,678,682	-76,193,504	-102,002,958	-112,368,982	-59,508,257	9
Purchase of property and equipment	118,853	196,635	2	26,073	73,410	3	2	4	13	14	14	5
Net cash used in investing activities	-118,853	-3,131,819	-4,040,743	-1,741,575	904,583	15	-2,095,600	-3,811,838	-12,724,680	-13,511,258	-13,911,171	-5
Acquisition of intangible assets	-	-	-	-	-	-	-	-	-	-	-	0
Net cash used in investing activities	-118,853	-3,131,819	-4,040,743	-1,741,575	904,583	15	-2,095,600	-3,811,838	-12,724,680	-13,511,258	-13,911,171	-5
Principal payments on notes payable	200,000	-	-	15	-	20	-	30	-	-	100	159
Proceeds from issuance of common stock, net of offering expenses	17	27	-	10	14	39	43	48	131	121	65	-
The cash outflow for payment of debt refinancing fees.	-	-	-	-	-	-	-	-	-830,000	-	2	11
Proceeds from issuance of note payable	4	1,000,000	10	-	-	-	-	-	-	-	152	135
Amount of cash outflow related to taxes on vested Restricted Stock Units.	-	-	-	-	-	-	-	-	-	61,598	3	1
Payments on finance lease obligations	-	-	-	-	-	-	-	-	-	34,299	36,684	0
Net proceeds from the exercise of stock options	-	-	-	49,227	-	7,504	13,007	75,048	13,432	-	175,015	1
Payment of deferred financing fees	-	-	-	-	-	-	-	-	-	-	3	2
Amount of cash outflow for end of term fee.	-	-	-	-	-	-	-	-	-	-	-	2
Net cash (used in) provided by financing activities	19	28	10	10	17	61	43	80	144	121	109	-39
Payment of deferred financing fees	-	-	-	-	-	-	-	-	-	-	3	2
Net cash (used in) provided by financing activities	19	28	10	10	17	61	43	80	144	121	109	-39
Net (decrease) increase in cash and cash equivalents	-	-	-	-	-	-	-	-	-	-4,832,034	35	-35